"By Lisa Naingggolan
Medscape Medical News
The European Union has given the nod to a new formulation of insulin glargine (Toujeo, Sanofi), which is a higher-strength insulin (300 units/mL) than the existing insulin glargine"...
Mild to moderate episodes of hypoglycemia usually can be treated with oral glucose. Adjustments in drug dosage, meal patterns, or exercise, may be needed.
Severe episodes of hypoglycemia with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery.
EXUBERA (insulin human [rdna origin]) is contraindicated in patients hypersensitive to EXUBERA (insulin human [rdna origin]) or one of its excipients. EXUBERA (insulin human [rdna origin]) is contraindicated in patients who smoke or who have discontinued smoking less than 6 months prior to starting EXUBERA (insulin human [rdna origin]) therapy. If a patient starts or resumes smoking, EXUBERA (insulin human [rdna origin]) must be discontinued immediately due to the increased risk of hypoglycemia, and an alternative treatment must be utilized (see CLINICAL PHARMACOLOGY, Special Populations, Smoking). The safety and efficacy of EXUBERA (insulin human [rdna origin]) in patients who smoke have not been established.
EXUBERA (insulin human [rdna origin]) is contraindicated in patients with unstable or poorly controlled lung disease, because of wide variations in lung function that could affect the absorption of EXUBERA (insulin human [rdna origin]) and increase the risk of hypoglycemia or hyperglycemia.
Last reviewed on RxList: 12/11/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Exubera Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find tips and advances in treatment.